c1 - transparency - shum - salon b
DESCRIPTION
TRANSCRIPT
Transparency in the Evaluation & Funding Process
How far can we go?
David Shum, PharmD, MBA
Director, Reimbursement & Health Economics
Roche Pharmaceuticals
2013 CADTH Symposium
St. John’s, NL
May 6, 2013
Increasing focus on transparency issues
Ref: Google ngram viewer
1900 1950 2000
‘‘committed to transparency’’- US delegation (NYT, March 2013)
‚supersecretive in one part about our products…but there are other areas where we will be completely transparent‛
Source: BusinessWeek, Dec 2012
Source: FT, April 2013
Transparency Index across HTA countries
Ref: Roche data
Fair & open process
Principles: priority setting
Patient / stakeholders
CCI
Patient data
Resources
Government
Information should be exempt from the general rule of public access
Disclosure of information would prejudice their economic interest
‚any prejudice to the Ministry’s economic interest in this regard has a repercussive, concomitant negative impact on the government’s financial interest…‛
Industry
Information should be exempt from the general rule of public access
Commercial information - confidential business tactics, strategies, and plans
• Positive steps to increasing
transparency in trial data and
HTA
• Tradeoffs between total
transparency and opacity
Towards increasing transparency
We Innovate Healthcare